Eric Padron is an Oncology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 932 publications with 15,706 citations (h-index 53); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 336129416
Telephone
813-745-7365Provider last certified this registry record 5 Mar 2025.
Clinical trials
- Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Geron CorporationProgram year20252 payments
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- SOBI, INCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Antimetabolite25%Hydroxyurea100%Part D<11 patientsIsocitrate Dehydrogenase 2 Inhibitor15.4%Idhifa100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia
H. Lee Moffitt Cancer Ctr & Res Inst
FY2026$495,033R01CA278300 - The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$522,013R01CA278300 - Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$477,698R37CA234021
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes
Journal of Clinical Oncology
2021 - RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis
Nature Communications
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Hatem Soliman, MD
Moffitt Cancer Center
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”